SCM
TXMD icon

Squadron Capital Management’s TherapeuticsMD TXMD Stock Holding History

Squadron Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-420,421
Closed -$849K – 56
2026
Q1 		$849K Buy
+420,421
New +$945K 0.31% 34

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Squadron Capital Management's TXMD Position: Q2 2026 in Review

Squadron Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2026, closing a stake of 420,421 shares — an estimated $849K sold.

Squadron Capital Management first reported a position in TXMD in Q1 2026 and held it in 1 quarter. The position peaked at $849K in Q1 2026. 45 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Squadron Capital Management reported no remaining TherapeuticsMD position as of Q2 2026 after selling out during the quarter.
  • Squadron Capital Management sold 420,421 TherapeuticsMD shares in Q2 2026, an estimated $849K.
  • Squadron Capital Management first reported a position in TherapeuticsMD in Q1 2026 and held it in 1 quarter.
  • Squadron Capital Management's TherapeuticsMD position peaked at $849K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.